Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of lanreotide Autogel 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide Autogel 120 mg administered every 28 days

Next Previous
Trial Profile

Efficacy and safety of lanreotide Autogel 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide Autogel 120 mg administered every 28 days

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Intestinal cancer; Neuroendocrine tumours; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms CLARINET FORTE
  • Sponsors Ipsen

    • Most Recent Events

    • 08 Mar 2022 According to an Ipsen media release, data published in 19th Annual European Neuroendocrine Tumor Society (ENETS) Conference.
    • 27 Sep 2021 Results published in the European Journal of Cancer
    • 22 Feb 2021 Results presented in an Ipsen media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top